Waheed: Award will bring recognition to Unani medicine

Medicine for vitiligo awaiting US FDA clearance, says doctor who was selected for Padma Shri

January 26, 2017 11:17 pm | Updated 11:18 pm IST

Mohammed Abdul Waheed

Mohammed Abdul Waheed

HYDERABAD: Dr.Mohammed Abdul Waheed, a Unani doctor well known for his research work and 35 years of experience in clinical management of vitiligo, is an elated man after being selected for the Padma Shri award.

“This will bring recognition to Unani medicine. I am really thankful to Government of India. God is great,” he said. Sharing his happiness, the Padma Shri awardee in the field of medicine told The Hindu that importantly it would help in bringing global recognition to Unani medicine.

Dr. Waheed, who graduated in Unani medicine and Surgery from Osmania University in 1978, was the former head of Central Research Institute of Unani Medicine under the Department of Ayush, Government of India. With expertise in phase II and phase III clinical trials, he had treated over two lakh vitiligo patients. “We are working for globalisation of Unani medicine. A drug dossier for vitiligo has been submitted to USFDA by the Central Council for Research in Unani Medicine. If approved the medicine could be globally utilised to treat and manage vitiligo,” he said. Recipient of several prestigious awards for his research including the AIIMS’s Best Scientist Award, he Dr.Waheed developed 17 Unani formulations for the effective management of vitiligo. and also coordinated multi-centric clinical trials of Unani medicines on Diabetes, Hypertension and Hepatitis.

Finding treatment for vitiligo mainly caused by autoimmune disorder — that affects one % of world and three to four % of Indian population — was close to his heart as the condition caused social discomfort and depression to patients, he said.

0 / 0
Sign in to unlock member-only benefits!
  • Access 10 free stories every month
  • Save stories to read later
  • Access to comment on every story
  • Sign-up/manage your newsletter subscriptions with a single click
  • Get notified by email for early access to discounts & offers on our products
Sign in

Comments

Comments have to be in English, and in full sentences. They cannot be abusive or personal. Please abide by our community guidelines for posting your comments.

We have migrated to a new commenting platform. If you are already a registered user of The Hindu and logged in, you may continue to engage with our articles. If you do not have an account please register and login to post comments. Users can access their older comments by logging into their accounts on Vuukle.